Pharmafile Logo

Redvax

- PMLiVE

Pfizer’s leukaemia drug Mylotarg backed for use in EU

The CHMP’s positive opinion could see the drug return to market after almost eight years

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist

Hiding between the lines of any company’s ledgers is an intangible asset, invisible to most auditors, but with the potential to have a very real impact on bottom line. Pharma...

Evoke Mind+Matter

- PMLiVE

Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

Bavencio fails a key lung cancer trial

- PMLiVE

J&J’s Erleada first US drug for non-metastatic prostate cancer

Drug approved by the FDA on the back of data from the SPARTAN study

- PMLiVE

Pfizer files third-gen ALK inhibitor for lung cancer

The US FDA is set to make a decision on lorlatinib later this year

- PMLiVE

PROSPER data reveal big Xtandi benefit in early-stage prostate cancer

Findings demonstrated a 71% reduction in cancer spreading and death

- PMLiVE

EC grants MSD’s Prevymis orphan product designation

The product will gain some market exclusivity benefits in CMV infection

- PMLiVE

Pfizer and IBM’s tech-enabled ‘Parkinson’s house’

Pharma firm looks to technology to help it unlock the doors to breakthrough treatments

Shire Basingstoke

Shire’s Maribavir wins US breakthrough therapy designation

It's based on phase II data for the transplant infection treatment

- PMLiVE

Pfizer drops neuroscience R&D, cutting 300 jobs

The new direction will see the termination of early-stage Parkinson’s and Alzheimer’s candidates

- PMLiVE

Pfizer buys into Sangamo’s motor neuron disease gene therapy

The pharma giant will pay $12m upfront and $150m in potential milestones

National Institute for Health and Care Excellence NICE logo

NICE to look again at Pfizer’s Besponsa after appeal

The blood cancer medicine was originally turned down on cost-effectiveness grounds

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links